Hakon Hakonarson
Founder Arctic Therapeutics
Seminars
Wednesday 2nd December 2026
Translating Biomarkers from Blood & Peripheral Tissues into Multimodal CNS Assessment
3:00 pm
- How a rare genetically driven amyloid disease, Hereditary Cystatin C Amyloid Angiopathy (HCCAA), can inform Alzheimer’s treatment by evaluating alternative biomarkers, including skin biopsies, reduced glutathione levels, and blood-based measurements of amyloid oligomerization
- How combining tissue-based, skin and blood-based biomarkers, and redox signals in HCCAA can help establish biological concordance and strengthen interpretation of systemic markers of amyloid pathology. And how these biomarkers can inform and functionally characterize diverse contributors of disease progression, such as impaired perivascular clearance mechanisms and extracellular matrix (ECM) remodelling. These measurements are extremely relevant to HCCAA with implications for Cerebral Amyloid Angiopathies (CAAs), as well as Alzheimer’s disease
- How these findings are being translated into Alzheimer’s biomarker studies, where blood-based assays are combined with advanced brain imaging to assess their relevance to broader pathology underpinned by amyloid aggregation
